Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Promising combo aims to wipe out leukemia cells in younger patients

NCT ID NCT02251548

First seen Nov 01, 2025 · Last updated Jun 16, 2026 · Updated 33 times

Summary

This study tests a new drug, ibrutinib, added to standard chemotherapy (FCR) for younger patients with untreated chronic lymphocytic leukemia (CLL). The goal is to see if this combination can clear all signs of leukemia from the bone marrow (called MRD-negative complete response). About 85 participants will receive the treatment and be followed for up to 2 years after stopping ibrutinib to check for lasting remission.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02215, United States

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Duke University Medical Center

    Durham, North Carolina, 27710, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • University of Kansas Cancer Center

    Westwood, Kansas, 66205, United States

  • University of Miami Sylvester Comprehensive Cancer Center

    Coral Gables, Florida, 33146, United States

  • University of Miami Sylvester Comprehensive Cancer Center

    Deerfield Beach, Florida, 33442, United States

  • Unversity of Miami Sylvester Comprehensve Cancer Center

    Miami, Florida, 33136, United States

  • West Michigan Cancer Center

    Kalamazoo, Michigan, 49007, United States

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.